Millennium Management
GTBP icon

Millennium Management’s GT Biopharma GTBP Stock Holding History

Millennium Management’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,198
Closed -$16.8K – 6364
2023
Q4 		$16.8K Sell
2,198
-736
-25% -$5.38K ﹤0.01% 5662
2023
Q3 		$21.2K Sell
2,934
-4,895
-63% -$40.5K ﹤0.01% 5639
2023
Q2 		$73.3K Buy
7,829
+3,065
+64% +$31.8K ﹤0.01% 5397
2023
Q1 		$79K Buy
4,764
+367
+8% +$8.41K ﹤0.01% 5497
2022
Q4 		$118K Sell
4,397
-736
-14% -$36.8K ﹤0.01% 5519
2022
Q3 		$271K Sell
5,133
-3,006
-37% -$230K ﹤0.01% 5453
2022
Q2 		$730K Buy
+8,139
New +$617K ﹤0.01% 4660
2021
Q4 		– Sell
-1,138
Closed -$230K – 7020
2021
Q3 		$230K Buy
+1,138
New +$342K ﹤0.01% 6020
2021
Q2 		– Sell
-930
Closed -$191K – 6734
2021
Q1 		$191K Buy
+930
New +$162K ﹤0.01% 5510

Other funds holding GTBP

Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Millennium Management's GTBP Position: Q1 2024 in Review

Millennium Management sold out of GT Biopharma (GTBP) in Q1 2024, closing a stake of 2,198 shares — an estimated $16.8K sold.

Millennium Management first reported a position in GTBP in Q1 2021 and held it in 9 quarters. The position peaked at $730K in Q2 2022. 17 funds tracked by Wall St. Rank hold GTBP as of Q1 2024.

  • Millennium Management reported no remaining GT Biopharma position as of Q1 2024 after selling out during the quarter.
  • Millennium Management sold 2,198 GT Biopharma shares in Q1 2024, an estimated $16.8K.
  • Millennium Management first reported a position in GT Biopharma in Q1 2021 and held it in 9 quarters.
  • Millennium Management's GT Biopharma position peaked at $730K in Q2 2022.
  • 17 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2024.

Based on Millennium Management's 13F filing for Q1 2024, filed 15 May 2024.